Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
$2.76
+1.1%
$2.12
$0.91
$5.85
$231.05M2.152.65 million shs2.54 million shs
enGene Holdings Inc. stock logo
ENGN
enGene
$3.79
+3.0%
$3.60
$2.65
$11.00
$193.69M-0.42123,343 shs44,123 shs
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
$3.63
-0.7%
$3.77
$3.36
$12.22
$145.15M1.114,493 shs408 shs
Cardiff Oncology, Inc. stock logo
TROV
Cardiff Oncology
$4.28
-3.8%
$16.75
$0.70
$3.46
$47.13M1.04648,892 shs1.59 million shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
0.00%-4.17%+17.45%+114.79%-51.75%
enGene Holdings Inc. stock logo
ENGN
enGene
0.00%+14.50%+15.20%-5.25%-58.21%
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
0.00%+2.23%-3.33%-8.69%-44.40%
Cardiff Oncology, Inc. stock logo
TROV
Cardiff Oncology
-3.82%+5.16%+41.72%+50.18%+64.62%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
4.157 of 5 stars
3.22.00.04.33.22.50.6
enGene Holdings Inc. stock logo
ENGN
enGene
2.9295 of 5 stars
3.53.00.00.02.12.50.6
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
2.9671 of 5 stars
3.85.00.00.00.00.00.6
Cardiff Oncology, Inc. stock logo
TROV
Cardiff Oncology
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
2.31
Hold$4.7070.29% Upside
enGene Holdings Inc. stock logo
ENGN
enGene
3.00
Buy$23.29514.40% Upside
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
3.50
Strong Buy$12.00231.03% Upside
Cardiff Oncology, Inc. stock logo
TROV
Cardiff Oncology
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest TROV, ENGN, EDIT, and MOLN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/13/2025
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$8.00 ➝ $4.00
4/29/2025
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
4/29/2025
enGene Holdings Inc. stock logo
ENGN
enGene
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$18.00 ➝ $18.00
4/28/2025
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$3.00
4/28/2025
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$3.00
(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
$32.31M7.15N/AN/A$1.63 per share1.69
enGene Holdings Inc. stock logo
ENGN
enGene
N/AN/AN/AN/A$5.35 per shareN/A
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
$5.65M25.91N/AN/A$3.99 per share0.91
Cardiff Oncology, Inc. stock logo
TROV
Cardiff Oncology
$250K188.51N/AN/A$0.94 per share4.55
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
-$237.09M-$3.04N/AN/AN/A-701.06%-139.24%-63.87%8/6/2025 (Estimated)
enGene Holdings Inc. stock logo
ENGN
enGene
-$55.14M-$1.65N/AN/AN/AN/A-32.60%-28.26%9/10/2025 (Estimated)
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
-$61.39M-$1.92N/AN/AN/AN/A-42.20%-38.12%8/25/2025 (Estimated)
Cardiff Oncology, Inc. stock logo
TROV
Cardiff Oncology
-$16.41M-$2.80N/AN/A-3,688.31%-202.00%-122.92%N/A

Latest TROV, ENGN, EDIT, and MOLN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
-$0.40N/AN/AN/A$1.81 millionN/A
6/10/2025Q2 2025
enGene Holdings Inc. stock logo
ENGN
enGene
-$0.4768-$0.51-$0.0332-$0.51N/AN/A
5/15/2025Q1 2025
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
-$0.3855-$0.50-$0.1145-$0.50N/AN/A
5/12/2025Q1 2025
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
-$0.51-$0.43+$0.08-$0.92$0.79 million$4.66 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
N/AN/AN/AN/AN/A
enGene Holdings Inc. stock logo
ENGN
enGene
N/AN/AN/AN/AN/A
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
N/AN/AN/AN/AN/A
Cardiff Oncology, Inc. stock logo
TROV
Cardiff Oncology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
N/A
3.08
3.08
enGene Holdings Inc. stock logo
ENGN
enGene
0.09
12.66
12.66
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
N/A
15.28
15.28
Cardiff Oncology, Inc. stock logo
TROV
Cardiff Oncology
0.12
2.37
2.37

Institutional Ownership

CompanyInstitutional Ownership
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
71.90%
enGene Holdings Inc. stock logo
ENGN
enGene
64.16%
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
26.55%
Cardiff Oncology, Inc. stock logo
TROV
Cardiff Oncology
9.99%

Insider Ownership

CompanyInsider Ownership
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
2.10%
enGene Holdings Inc. stock logo
ENGN
enGene
10.40%
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
5.93%
Cardiff Oncology, Inc. stock logo
TROV
Cardiff Oncology
0.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
23083.71 million81.96 millionOptionable
enGene Holdings Inc. stock logo
ENGN
enGene
3151.10 million45.79 millionN/A
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
18040.38 million37.98 millionNot Optionable
Cardiff Oncology, Inc. stock logo
TROV
Cardiff Oncology
N/A11.01 millionN/ANot Optionable

Recent News About These Companies

Cardiff Oncology announces second patent for onvansertib combination
William Blair Keeps Their Buy Rating on Cardiff Oncology (CRDF)
Cardiff Oncology Reports Positive Q3 2024 Results and Clinical Progress

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Editas Medicine stock logo

Editas Medicine NASDAQ:EDIT

$2.76 +0.03 (+1.10%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$2.73 -0.03 (-1.09%)
As of 07/18/2025 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

enGene stock logo

enGene NASDAQ:ENGN

$3.79 +0.11 (+2.99%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$3.69 -0.10 (-2.64%)
As of 07/18/2025 05:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

Molecular Partners stock logo

Molecular Partners NASDAQ:MOLN

$3.62 -0.03 (-0.68%)
Closing price 07/18/2025 03:27 PM Eastern
Extended Trading
$3.62 0.00 (0.00%)
As of 07/18/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Cardiff Oncology stock logo

Cardiff Oncology NASDAQ:TROV

Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.